Prevalence Survey of Antimalarial Drug Resistance Markers

NCT03217851 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4000

Last updated 2022-06-28

No results posted yet for this study

Summary

Study is cross-sectional and observational with one-time dried-blood spot sample collection from persons with laboratory-confirmed uncomplicated Plasmodium falciparum malaria (mixed or monoinfection). Samples will be analysed for the presence of molecular markers of resistance to ACT partner drugs (gene amplifications and/or other mutations in pfmdr1, gene amplifications of pfpm2, and additional mutations which may be identified during the course of the trial) in the first instance. Testing to detect additional markers of antimalarial drug resistance will also be performed where feasible. Prevalence of mutations will be summarized and mapped to provide intelligence on antimalarial drug resistance in the region of interest.

Conditions

Interventions

DIAGNOSTIC_TEST

Blood Collection

blood smear and/or rapid diagnostic

DIAGNOSTIC_TEST

Dried Blood Spot

Dried Blood Spot on filter paper

Sponsors & Collaborators

  • Mahidol University

    collaborator OTHER
  • Worldwide Antimalarial Resistance Network

    collaborator NETWORK
  • Mahidol Oxford Tropical Medicine Research Unit

    collaborator OTHER
  • Myanmar Oxford Clinical Research Unit

    collaborator OTHER
  • Shoklo Malaria Research Unit

    collaborator OTHER
  • Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit

    collaborator OTHER
  • Oxford University Clinical Research Unit, Vietnam

    collaborator OTHER
  • Cambodia Oxford Medical Research Unit

    collaborator UNKNOWN
  • University of Oxford

    lead OTHER

Principal Investigators

  • Francois Nosten, Prof · Shoklo Malaria Research Unit

  • Frank Smithuis, Prof · Myanmar Oxford Clinical Research Unit

  • Mayfong Mayxay, Prof · Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit

  • Nguyen Thanh Thuy Nhien, Dr · Oxford University Clinical Research Unit, Vietnam

  • Arjen M. Dondorp, PhD · Mahidol Oxford Clinical Research Unit

Eligibility

Min Age
6 Months
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-18
Primary Completion
2021-12-24
Completion
2021-12-24

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03217851 on ClinicalTrials.gov